- Home
- ANGO vs FDMT Comparison
ANGO vs FDMT Comparison
Compare ANGO & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- FDMT
- Stock Information
- Founded
- ANGO 1988
- FDMT 2013
- Country
- ANGO United States
- FDMT United States
- Employees
- ANGO N/A
- FDMT N/A
- Industry
- ANGO Medical/Dental Instruments
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- FDMT Health Care
- Exchange
- ANGO Nasdaq
- FDMT Nasdaq
- Market Cap
- ANGO 400.8M
- FDMT 192.2M
- IPO Year
- ANGO 2004
- FDMT 2020
- Fundamental
- Price
- ANGO $10.94
- FDMT $7.15
- Analyst Decision
- ANGO Strong Buy
- FDMT Buy
- Analyst Count
- ANGO 3
- FDMT 9
- Target Price
- ANGO $19.00
- FDMT $30.63
- AVG Volume (30 Days)
- ANGO 387.1K
- FDMT 520.4K
- Earning Date
- ANGO 10-02-2025
- FDMT 11-12-2025
- Dividend Yield
- ANGO N/A
- FDMT N/A
- EPS Growth
- ANGO N/A
- FDMT N/A
- EPS
- ANGO N/A
- FDMT N/A
- Revenue
- ANGO $292,498,000.00
- FDMT $33,000.00
- Revenue This Year
- ANGO $7.13
- FDMT $8,572.97
- Revenue Next Year
- ANGO $6.28
- FDMT N/A
- P/E Ratio
- ANGO N/A
- FDMT N/A
- Revenue Growth
- ANGO N/A
- FDMT N/A
- 52 Week Low
- ANGO $5.83
- FDMT $2.24
- 52 Week High
- ANGO $13.50
- FDMT $17.41
- Technical
- Relative Strength Index (RSI)
- ANGO 68.67
- FDMT 60.84
- Support Level
- ANGO $10.34
- FDMT $6.60
- Resistance Level
- ANGO $11.04
- FDMT $7.21
- Average True Range (ATR)
- ANGO 0.33
- FDMT 0.40
- MACD
- ANGO -0.01
- FDMT -0.05
- Stochastic Oscillator
- ANGO 83.49
- FDMT 82.52
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.